Heron Therapeutics, Inc. (NASDAQ:HRTX) Shares Sold by Millennium Management LLC

Millennium Management LLC lowered its position in shares of Heron Therapeutics, Inc. (NASDAQ:HRTX) by 54.7% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,434,627 shares of the biotechnology company’s stock after selling 1,732,659 shares during the quarter. Millennium Management LLC owned approximately 0.95% of Heron Therapeutics worth $5,021,000 as of its most recent SEC filing.

A number of other hedge funds have also made changes to their positions in HRTX. AQR Capital Management LLC increased its holdings in shares of Heron Therapeutics by 1,460.9% in the second quarter. AQR Capital Management LLC now owns 607,135 shares of the biotechnology company’s stock valued at $2,125,000 after purchasing an additional 568,238 shares during the last quarter. Caxton Associates LP acquired a new stake in shares of Heron Therapeutics in the second quarter valued at $708,000. Squarepoint Ops LLC raised its stake in shares of Heron Therapeutics by 369.0% in the second quarter. Squarepoint Ops LLC now owns 363,700 shares of the biotechnology company’s stock valued at $1,273,000 after acquiring an additional 286,160 shares in the last quarter. Marshall Wace LLP raised its stake in shares of Heron Therapeutics by 256.2% in the second quarter. Marshall Wace LLP now owns 1,761,051 shares of the biotechnology company’s stock valued at $6,164,000 after acquiring an additional 1,266,697 shares in the last quarter. Finally, Profund Advisors LLC acquired a new stake in shares of Heron Therapeutics in the second quarter valued at $168,000. Institutional investors and hedge funds own 80.01% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, Needham & Company LLC restated a “buy” rating and issued a $5.00 price target on shares of Heron Therapeutics in a research note on Wednesday, September 25th.

Heron Therapeutics Price Performance

Shares of NASDAQ:HRTX opened at $1.84 on Friday. The business’s 50 day simple moving average is $1.96 and its 200-day simple moving average is $2.68. The firm has a market capitalization of $277.20 million, a price-to-earnings ratio of -3.02 and a beta of 1.80. Heron Therapeutics, Inc. has a 12 month low of $0.50 and a 12 month high of $3.93.

Heron Therapeutics (NASDAQ:HRTX) last announced its quarterly earnings results on Tuesday, August 6th. The biotechnology company reported ($0.06) EPS for the quarter, missing the consensus estimate of ($0.04) by ($0.02). The firm had revenue of $36.02 million during the quarter, compared to analyst estimates of $35.35 million. During the same quarter last year, the business earned ($0.35) earnings per share. On average, equities analysts anticipate that Heron Therapeutics, Inc. will post -0.1 earnings per share for the current year.

About Heron Therapeutics

Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.